drugset / Trial / NCT01014481

Appropriate Timing of HAART in Co-infected HIV/TB Patients

NCT01014481

RandomizedParallel-groupOpen-labelTreatment

Summary

To study the optimal timing to initiate antiretroviral therapy in HIV-infected patients who are receiving tuberculosis treatment between at 4 weeks and at 12 weeks after tuberculosis treatment by comparing the composite end point of death rate, hospitalization rate and adverse drug reactions at week 48, 96 and 144.

Timeline

Start
2009-10
Primary completion
2011-05
Completion
2011-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Efavirenz Other / unclassified 600 mg
Subject Lamivudine Other / unclassified 300 mg
Subject Tenofovir Small molecule 300 mg